Biochemical markers in heart failure: Are they all the same?;Marcadores bioquímicos en la insuficiencia cardíaca: ¿Todos iguales?

Revista Espanola de Cardiologia

Volumn 58, Issue 3, 2005, Pages 241-243

  Anguita Sánchez, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; OMAPATRILAT; VASOPRESSIN;

DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; EDITORIAL; HEART FAILURE; HUMAN; HYPERTENSION; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 17144425693     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072470     Document Type: Editorial

References (11)

1. Roig E. Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:347-56.
2. Cohn JN, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-23.
3. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994;308:1615-20.
4. Eriksson SV, Eneroth P, Kjekshus J, Offstad J, Swedberg K. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the CONSENSUS study. Clin Cardiol. 1994;17:603-6.
5. Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, et al. Plasma big endothelin 1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol. 1993;71:1293-9.
6. Kirk V, Bay M, Parner J, Krogsgaard K, Herzogm TM, Boesgaard C, et al. N-terminal proBNP and mortality in hospitalized patients with heart failure and preserved versus reduced systolic function. Data from the CHHF study. Eur J Heart Fail. 2004;6:335-44.
7. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant O, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail. 2004;6:269-74.
8. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail. 2004;6:351-4.
9. Anguita M. Diagnóstico y tratamiento de la insuficiencia cardíaca diastólica. Rev Esp Cardiol. 2004;57:570-5.
10. Rivera M, Cortés R, Portolés M, Valero R, Sancho-Tello MJ, Martínez-Dolz L, et al. Relación de los valores plasmáticos de big endotelina-1 con NT-proBNP y la función ventricular de pacientes con insuficiencia cardíaca. Rev Esp Cardiol. 2005;58:276-82.
11. Davis ME, Troughton RW, Nicholls G, Yandle TG, Framptom CM, Richards M, et al. Introduction of betablockers causes an initial increase in plasma brain natriuretic peptide and N-terminal brain natriuretic peptide levels in patients with stable systolic heart failure [abstract]. Circulation. 2004;110:III-600.